Review
Copyright ©2011 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Radiol. Mar 28, 2011; 3(3): 66-69
Published online Mar 28, 2011. doi: 10.4329/wjr.v3.i3.66
Applications of new irradiation modalities in patients with lymphoma: Promises and uncertainties
Youlia M Kirova, Cyrus Chargari
Youlia M Kirova, Cyrus Chargari, Department of Radiation Oncology, Institut Curie 26, rue d’Ulm, 75248 Paris, Cedex 05, France
Author contributions: Kirova YM designed the study; Kirova YM and Chargari C wrote the paper.
Correspondence to: Youlia M Kirova, MD, Department of Radiation Oncology, Institut Curie 26, rue d’Ulm, 75248 Paris, Cedex 05, France. youlia.kirova@curie.net
Telephone: +33-1-44324193 Fax: +33-1-53102653
Received: January 15, 2011
Revised: March 2, 2011
Accepted: March 9, 2011
Published online: March 28, 2011
Abstract

New highly conformal irradiation modalities have emerged for treatment of Hodgkin lymphoma. Helical tomotherapy offers both intensity-modulated irradiation and accurate patient positioning and was shown to significantly decrease radiation doses to the critical organs. Here we review some of the most promising applications of helical tomotherapy in Hodgkin disease. By decreasing doses to the heart or the breast, helical tomotherapy might decrease the risk of long-term cardiac toxicity or secondary breast cancers, which are major concerns in patients receiving chest radiotherapy. Other strategies, such as debulking radiotherapy prior to stem cell transplantation or total lymphoid irradiation may be clinically relevant. However, helical tomotherapy may also increase the volume of tissues that receive lower doses, which has been implicated in the carcinogenesis process. Prospective assessments of these new irradiation modalities of helical tomotherapy are required to confirm the potential benefits of highly conformal therapies applied to hematological malignancies.

Keywords: Hodgkin lymphoma; Helical tomotherapy; Cardiac toxicity; Secondary cancers